1. Long-term survival in patients with advanced non–small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study. (January 2019) Authors: von Pawel, J.; Bordoni, R.; Satouchi, M.; Fehrenbacher, L.; Cobo, M.; Han, J.Y.; Hida, T.; Moro-Sibilot, D.; Conkling, P.; Gandara, D.R.; Rittmeyer, A.; Gandhi, M.; Yu, W.; Matheny, C.; Patel, H.; Sandler, A.; Ballinger, M.; Kowanetz, M.; Park, K. Journal: European journal of cancer Issue: Volume 107(2019) Page Start: 124 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗